Anaplastic Astrocytoma Treatment Market, by Product Type (Alkylating Agents, Kinase Inhibitors, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Geography - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

  • To Be Published : Jul 2018 |
  • Format :  

Astrocytoma is a medical condition that develops from astrocytes, a star-shaped brain cells. The disease has been categorized into four different groups based on reproduction rate of the cell, and its capability to spread in nearby tissues. Grades I and Grades II astrocytomas are non-malignant, and can be referred to as low grade. However, Grades III and Grades IV are malignant, and has the capacity to spread quickly. With time, lower grade astrocytoma can change to high grade astrocytoma. Grade III astrocytomas are also called as anaplastic astrocytomas. Anaplastic Astrocytoma is a rare medical condition, and can be divided into two categories - IDH-mutant, IDH-wildtype. IDH1 is a gene that encodes for a metabolic enzyme called isocitrate dehydrogenase 1. According to American Brain Tumor Association, about 25,000 new cases of primary malignant brain tumors were diagnosed in the U.S. in 2016. Moreover, about 50% of gliomas are glioblastomas. Occurrence of anaplastic astrocytomas is more common in adults compared to children, according to American Brain Tumor Association (ABTA). The ABTA estimates that anaplastic astrocytomas in people aged 30-35 years accounted for 17% of primary malignant brain tumors, however, only 9% of tumor in children are glioblastomas.

Anaplastic Astrocytoma Treatment Market: Driver

Increasing number of drug candidate in pipeline, which may receive approval over the forecast period is expected to drive growth of the global anaplastic astrocytoma treatment market. Currently, there is only a drug, temozolomide (Temodar), approved by U.S. FDA for Anaplastic Astrocytoma. Temodar is an alkylating agent that has been approved for both conditions, newly diagnosed patients as well as refractory anaplastic astrocytoma patients, who have witnessed disease progression in spite of taking drug containing nitrosourea and procarbazine. However, there are multiple products in pipeline for the treatment of anaplastic astrocytoma. For instance, DCC-2618, a drug candidate developed by Deciphera Pharmaceuticals, Inc. is currently in Phase 1 clinical trials. The drug has also been granted orphan drug designation for the treatment of anaplastic astrocytoma and glioblastoma multiforme (GBM) in September 2017. Moreover, an experimental drug PAC-1 was cleared for the clinical trial of patients with anaplastic astrocytoma in November 2017. The drug candidate is being developed by Vanquish Oncology, Inc. The trial will determine if the drug candidate is safe to use in combination with a standard chemotherapy drug, temozolomide.

Anaplastic Astrocytoma Treatment Market: Restraint

Currently, there are three main forms of treatment for anaplastic astrocytoma – surgery, radiation, and chemotherapy. Out of these three, surgery is the first line of treatment in most of the cases. Only if, whole tumor cannot be safely excised or removed, patients are advised to go for other method of treatment. This treatment pattern i.e. drugs as second or third line of treatment has hampered the sales of pharmaceutical drugs such as Temodar, which in turn has restrained growth of anaplastic astrocytoma treatment market.

Anaplastic Astrocytoma Treatment Market: Regional Analysis

North America is expected to account for major share in global anaplastic astrocytoma treatment market, owing to higher awareness about rare diseases such as anaplastic astrocytoma, and also, presence of leading clinical-stage companies in the region. For instance, a study sponsored by Burzynski Research Institute, headquartered at Texas, U.S., is testing antineoplaston therapy (atengenal + astugenal) in clinical trials. The study is currently in phase 2 clinical trials. Furthermore, a clinical trial sponsored by Northwell Health in collaboration with Genentech, Inc. (subsidiary of Roche AG) is testing safety and efficacy of Erlotinib for anaplastic astrocytoma. The study is currently in Phase 1/2. Approval of these pipeline products over the forecast period would boost growth of North America anaplastic astrocytoma treatment market.

Moreover, the approval of generics for temozolomide will play a vital role in increasing adoption of drug, especially in emerging economies in regions such as Asia Pacific and Latin America. In 2016, FDA approved the Amerigen Pharmaceuticals Limited’s generic version of Temodar. The company’s main facility is in Jiangsu Province, China. Leading global generic players such as Mylan N.V. has also received approval for generic version of Temodar in July 2016. The entry of generic drugs is expected to support growth of the anaplastic astrocytoma treatment market.

Anaplastic Astrocytoma Treatment Market: Key Players

Key players operating in anaplastic astrocytoma treatment market includes Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer, Inc., and Novartis AG. Roche AG has also product for anaplastic astrocytoma in pipeline, currently. Moreover, medium-sized generic manufacturers such as Perrigo Company Plc and Cipla Ltd. also have presence in the market.

Anaplastic Astrocytoma Treatment Market Taxonomy

The global anaplastic astrocytoma treatment market is segmented on the basis of product type, distribution channel, and geography:

By Product Type:

  • Alkylating Agents
  • Kinase Inhibitors
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geography

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.
Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.